CompletedInterventionalPhase 2Last updated Dec 19, 2011

Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests

A Multi-centre, Single-blind, Randomised, Parallel Group, Phase IIb Dose Rate Range Finding Study to Find Maintenance Dose Rate Range of ICI35,868 for the Minimal-to-moderate Sedation on Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)

Overview

ClinicalTrials.gov ID: NCT01189604
Lead Sponsor: AstraZenecaINDUSTRY
Brief Summary: Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Aug 2010
Primary Completion Date: Nov 2010Actual
Completion Date: Nov 2010Actual

Study Record Dates

First Submitted: Aug 25, 2010
First Submitted that Met QC Criteria: Aug 25, 2010
First Posted: Aug 26, 2010Estimated
Last Update Submitted that Met QC Criteria: Dec 15, 2011
Last Update Posted: Dec 19, 2011Estimated
Last Verified: Dec 2011

NCT01961349Completed

Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy

NCT01941888Completed

Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study

NCT06378879Not yet recruiting

Intermittent Boluses Versus Infusion of Propofol During Gastroscopy

NCT02062177Completed

Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy

NCT06358131Unknown status

Propofol Versus Midazolam in Sedation for Upper and Lower Gastrointestinal Endoscopy.

NCT02174588Completed

Moderate Sedation for Elective Upper Endoscopy With Balanced Propofol Versus Propofol Alone: a Randomized Clinical Trial